Abrysvo - Inpatient use is restricted to pregnant women at 32-36 weeks of gestation, following specific criteria for use, to provide passive immunity to the infant.
Criteria for Use in Pregnancy (all should be met):
Administration is during the CDC recommended seasonal time for use in pregnancy (September through January)
Patient is at 32-36 weeks gestation
Birth is expected to be at a minimum of 2 weeks after Abrysvo administration (dose given 3-4 weeks prior to birth is preferred and expected to provide even stronger immunity against RSV)
Patient is expected to have an extended hospital stay during pregnancy weeks 32–36
Patient is educated on the Abrysvo vaccination prior to administration (includes purpose, possible side effects, and the need to tell physicians and other healthcare providers of having received this vaccine).
RSV vaccines may be offered in Huntsville Hospital associated clinics. Abrysvo and Arexvy are classified as interchangeable. Utilization will based on cost, reimbursement, and hospital contracts for geriatric patients.
Add Formweb to your mobile device
Abrysvo - Inpatient use is restricted to pregnant women at 32-36 weeks of gestation, following specific criteria for use, to provide passive immunity to the infant.
Criteria for Use in Pregnancy (all should be met):
RSV vaccines may be offered in Huntsville Hospital associated clinics. Abrysvo and Arexvy are classified as interchangeable. Utilization will based on cost, reimbursement, and hospital contracts for geriatric patients.
Reviewed: October 2023
Respiratory Syncytial Virus Vaccine (Abrysvo) Spotlight
Respiratory Syncytial Virus Vaccine, Adjuvanted (Arexvy) Spotlight